Bollin, NICE Offices Manchester, Piccadilly Plaza, M1 4BT. Julian Evans (JE) Present for items 2-4. Fiona Lindop (FL) Present for items 1-6

Transcription

1 Parkinson s disease guideline committee meeting Date: 21/01/2016 Location: Minutes: Bollin, NICE Offices Manchester, Piccadilly Plaza, M1 4BT Draft Committee members present: Paul Cooper (Chair) Janine Barnes (JB) Alistair Church (AC) Debbie Davies (DD) Julian Evans (JE) Present for items 2-4 Robin Fackrell (RF) Richard Grunewald (RG) Fiona Lindop (FL) Present for items 1-6 Jane Little (JL) Lynne Osbourne (LO) Paul Shotbolt Matthew Sullivan (MS) Richard Walker (RW) In attendance: Gabriel Rogers (GR) Technical Adviser Health Economics Steven Ward (SW) Health Economist Sue Spiers (SS) Associate Director Present for items 1-4 Sarah Mills (SM) Project Manager Page 1 of 6

2 Aimely Lee (AL) Technical Analyst Kate Moring (KM) Business Analyst Present for items 2-4 & 8 Louise Bate Associate Director Medicines Education Present for items 5 & 6 Observers: None Committee member apologies: Graham Lennox Ivan Bennett Committee member Committee member 1. Welcome, introductions, minutes, DoI and matters arising The Chair welcomed the Committee members and attendees to the ninth meeting on Parkinson s disease. The Chair asked those present to declare any conflicts of interest relevant to the areas being discussed or potential new conflicts. Name Declaration Classification Chairs action Paul Cooper (PC) Member of the American Epilepsy Society guideline committee. Non-specific, personal, nonfinancial Association of British Neurologists, committee member of specialist advisory group Non-specific, personal, nonfinancial European Academy of Neurology Scientific Panel Brain Injury committee Non-specific, personal, nonfinancial Page 2 of 6

3 Fiona Lindop A lecture to the Association of Physiotherapists with an Interest in neurology (ACPIN) in Norwich in November entitled European Guidelines and Physiotherapy Management in Parkinson s. I was paid a fee of 250 for this. financial (noncommercial sector) I am on the Excellence Network National Oversight Board (representing therapy) and am also a member of the Service Development Group for this Network. I represent Physiotherapy on the National Audit of the NICE Guidelines for Parkinson s which is due to report the 2015 Audit later this year. Janine Barnes Member of 2 Excellence committees: Evidence based practice and development of a medicines management standard to be a statement of good practice. Page 3 of 6

4 Matthew Sullivan Member of the Research Support Development Team. non financial (honoraria in line with NICE lay member payments) Member of Excellence Network preparation of training materials for lay members. (honoraria paid in line with NICE lay members payments) Richard Walker Excellence network lead on care homes and ethnic minority groups Richard Grunewald Presentation of UCB funded lecture on clozapine at the Yorkshire Movement disorder group (honorarium donated to Parkinsons UK) It was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations. The committee reviewed the minutes of the previous meeting and agreed they were an accurate record of the discussions. Page 4 of 6

5 The Chair updated the committee on the impact of NHS England s policy on Duodopa on the development of the Parkinson s Disease guideline. PC confirmed that the main objectives for the day were to agree health economic modelling inputs and consider evidence for review question Approach to data in advanced PD stage review questions The committee considered the relevance of data from the PDSurg RCT for the review questions around advanced PD interventions. Agreement was reached as to what type of data analysis would be of most value clinically. 3 & 4. Health Economic modelling for advanced PD discussions The committee considered modelling inputs including, model structure and transitions, cost input and queries and quality of life inputs and queries. The committee agreed the assumptions which will be built into the health economic model. 5 & 6. Review Question 21 - What is the comparative effectiveness of antipsychotics for the treatment of symptoms of psychosis associated with Parkinson s disease? AL & GR presented evidence for review question 21, including a network metaanalysis. The committee discussed the evidence and made draft recommendations based on the evidence presented and their clinical experience and expertise. 7. Review protocols SW reported that the Medicines & Prescribing team had made some amendments to the review protocols for questions 14&19. The committee considered these amendments and made some further minor changes before agreeing the amended protocols. RQ 14 - What is the comparative effectiveness of levodopa preparations, monoamine oxidase B inhibitors, dopamine agonists and anticholinergics as first-line treatment of motor symptoms? RQ 19 - What is the comparative effectiveness of pharmacological interventions as Page 5 of 6

6 adjuvants to levodopa preparations? 8. Costing KM gave a presentation outlining the role of the resource impact assessment team and notified the committee that they would be seeking volunteers to assist with the costing work towards the end of the guideline development. 9. AOB. The Chair thanked the group for their attendance and contributions. SM confirmed the dates of the next meeting, advised that the LETR tables and chapters will be circulated for information and comment and confirmed the date and location of the next meeting. Date of next meeting: 10 & 11 March 2016 Location of next meeting: External venue, Manchester Page 6 of 6